» Articles » PMID: 28292717

Test-retest Reproducibility of Quantitative Binding Measures of [C]Ro15-4513, a PET Ligand for GABA Receptors Containing Alpha5 Subunits

Overview
Journal Neuroimage
Specialty Radiology
Date 2017 Mar 16
PMID 28292717
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Alteration of γ-aminobutyric acid "A" (GABA) receptor-mediated neurotransmission has been associated with various neurological and psychiatric disorders. [C]Ro15-4513 is a PET ligand with high affinity for α5-subunit-containing GABA receptors, which are highly expressed in limbic regions of the human brain (Sur et al., 1998). We quantified the test-retest reproducibility of measures of [C]Ro15-4513 binding derived from six different quantification methods (12 variants).

Methods: Five healthy males (median age 40 years, range 38-49 years) had a 90-min PET scan on two occasions (median interval 12 days, range 11-30 days), after injection of a median dose of 441 MegaBequerels of [C]Ro15-4513. Metabolite-corrected arterial plasma input functions (parent plasma input functions, ppIFs) were generated for all scans. We quantified regional binding using six methods (12 variants), some of which were region-based (applied to the average time-activity curve within a region) and others were voxel-based: 1) Models requiring arterial ppIFs - regional reversible compartmental models with one and two tissue compartments (2kbv and 4kbv); 2) Regional and voxelwise Logan's graphical analyses (Logan et al., 1990), which required arterial ppIFs; 3) Model-free regional and voxelwise (exponential) spectral analyses (SA; (Cunningham and Jones, 1993)), which also required arterial ppIFs; 4) methods not requiring arterial ppIFs - voxelwise standardised uptake values (Kenney et al., 1941), and regional and voxelwise simplified reference tissue models (SRTM/SRTM2) using brainstem or alternatively cerebellum as pseudo-reference regions (Lammertsma and Hume, 1996; Gunn et al., 1997). To compare the variants, we sampled the mean values of the outcome parameters within six bilateral, non-reference grey matter regions-of-interest. Reliability was quantified in terms of median absolute percentage test-retest differences (MA-TDs; preferentially low) and between-subject coefficient of variation (BS-CV, preferentially high), both compounded by the intraclass correlation coefficient (ICC). These measures were compared between variants, with particular interest in the hippocampus.

Results: Two of the six methods (5/12 variants) yielded reproducible data (i.e. MA-TD <10%): regional SRTMs and voxelwise SRTM2s, both using either the brainstem or the cerebellum; and voxelwise SA. However, the SRTMs using the brainstem yielded a lower median BS-CV (7% for regional, 7% voxelwise) than the other variants (8-11%), resulting in lower ICCs. The median ICCs across six regions were 0.89 (interquartile range 0.75-0.90) for voxelwise SA, 0.71 (0.64-0.84) for regional SRTM-cerebellum and 0.83 (0.70-0.86) for voxelwise SRTM-cerebellum. The ICCs for the hippocampus were 0.89 for voxelwise SA, 0.95 for regional SRTM-cerebellum and 0.93 for voxelwise SRTM-cerebellum.

Conclusion: Quantification of [C]Ro15-4513 binding shows very good to excellent reproducibility with SRTM and with voxelwise SA which, however, requires an arterial ppIF. Quantification in the α5 subunit-rich hippocampus is particularly reliable. The very low expression of the α5 in the cerebellum (Fritschy and Mohler, 1995; Veronese et al., 2016) and the substantial α1 subunit density in this region may hamper the application of reference tissue methods.

Citing Articles

NRM 2021 Abstract Booklet.

J Cereb Blood Flow Metab. 2021; 41(1_suppl):11-309.

PMID: 34905986 PMC: 8851538. DOI: 10.1177/0271678X211061050.


Reproducibility of findings in modern PET neuroimaging: insight from the NRM2018 grand challenge.

Veronese M, Rizzo G, Belzunce M, Schubert J, Searle G, Whittington A J Cereb Blood Flow Metab. 2021; 41(10):2778-2796.

PMID: 33993794 PMC: 8504414. DOI: 10.1177/0271678X211015101.


Basmisanil, a highly selective GABA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.

Hipp J, Knoflach F, Comley R, Ballard T, Honer M, Trube G Sci Rep. 2021; 11(1):7700.

PMID: 33833333 PMC: 8032764. DOI: 10.1038/s41598-021-87307-7.


Αlpha 5 subunit-containing GABA receptors in temporal lobe epilepsy with normal MRI.

McGinnity C, Barros D, Hinz R, Myers J, Yaakub S, Thyssen C Brain Commun. 2021; 3(1):fcaa190.

PMID: 33501420 PMC: 7811756. DOI: 10.1093/braincomms/fcaa190.


Enhancing Clinical Trials Through Synergistic Gamma Power Analysis.

Honda S, Matsumoto M, Tajinda K, Mihara T Front Psychiatry. 2020; 11:537.

PMID: 32587536 PMC: 7299152. DOI: 10.3389/fpsyt.2020.00537.


References
1.
Harada M, Kubo H, Nose A, Nishitani H, Matsuda T . Measurement of variation in the human cerebral GABA level by in vivo MEGA-editing proton MR spectroscopy using a clinical 3 T instrument and its dependence on brain region and the female menstrual cycle. Hum Brain Mapp. 2010; 32(5):828-33. PMC: 6870297. DOI: 10.1002/hbm.21086. View

2.
Sadzot B, Frost J, Wagner Jr H . In vivo labeling of central benzodiazepine receptors with the partial inverse agonist [3H]Ro 15-4513. Brain Res. 1989; 491(1):128-35. DOI: 10.1016/0006-8993(89)90094-2. View

3.
Crestani F, Keist R, Fritschy J, Benke D, Vogt K, Prut L . Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A. 2002; 99(13):8980-5. PMC: 124409. DOI: 10.1073/pnas.142288699. View

4.
Gousias I, Rueckert D, Heckemann R, Dyet L, Boardman J, Edwards A . Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest. Neuroimage. 2008; 40(2):672-684. DOI: 10.1016/j.neuroimage.2007.11.034. View

5.
Mendez M, Horder J, Myers J, Coghlan S, Stokes P, Erritzoe D . The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. Neuropharmacology. 2012; 68:195-201. PMC: 4489617. DOI: 10.1016/j.neuropharm.2012.04.008. View